Table 2. The rates of response (CCyR,... | American Society of Hematology

Table 2.

Results of the randomized trials comparing nilotinib 300 mg twice per day versus imatinib 400 mg once per day (ENESTnd), dasatinib 100 mg once per day versus imatinib 400 mg once per day (DASISION), and bosutinib 500 mg once per day versus imatinib 400 mg once per day (BELA)

The rates of response (CCyR, MR3, and MR4.5) are given as cumulative incidences. MR3 (MMR) is defined as a 3-log reduction in transcript levels or 0.1% on the international scale. PFS and OS are expressed as 2-year probabilities. Patients still on therapy at 24 mos are expressed as proportions. The columns with the heading “difference” indicate the difference in outcome between the second-generation TKI and imatinib.

*Statistically significant difference.

†Statistically nonsignificant difference.

View Large

This Feature Is Available To Subscribers Only